Engineered chimeric pegylated adi and methods of use
AssigneeTDW Group
InventorsBor-Wen Wu, Robert Almassy, Wei He, Richard E. Showalter, Jiaojuan He, Yunyun Guo, James A. Thomson
Life of this patent
Estimating the term…
Abstract
Provided are chimeric arginine deiminases, including pegylated chimeric arginine deiminases, and related compositions and methods of use thereof, including methods of treating cancer.
Claims54
A recombinant chimeric arginine deiminase (ADI) comprising a catalytic domain of an ADI protein derived from a first microorganism and an α-helical domain of an ADI protein derived from a second microorganism.
The recombinant chimeric ADI of clain 1, wherein the first microorganism is M. gateae and the second microorganism is M. arthritidis.
The recombinant chimeric ADI of claim wherein the first microorganism is M. phocidae and the second microorganism is M. phocicerebrale.
The recombinant chimeric ADI of any one of the preceding claims, wherein the recombinant chimeric ADI has been modified to remove at least one pegylation site.
The recombinant chimeric ADI of any one of the preceding claims, wherein at least one lysine residue has been modified by an amino acid substitution.
The recombinant chimeric ADI of any one of the preceding claims covalently bonded via a biocompatible linker to polyethylene glycol.
A polynucleotide encoding the recombinant chimeric ADI of any one of he preceding claims.
A composition comprising the recombinant chimeric ADI of any one of the preceding claims and a physiologically acceptable carrier.
Dependencies are inferred from the claim text.